The role of biologic agents in the management of common shoulder pathologies: current state and future directions.

J Shoulder Elbow Surg · Oct 01 2019 · Review

Carr JB, Rodeo SA

Department of Sports Medicine and Shoulder Surgery, Hospital for Special Surgery, New York

Shoulder & Elbow Sports Medicine

SUMMARY — THE REDUCTIONThis review finds that despite growing popularity, biologic agents like PRP and bone marrow/adipose-derived cells lack strong clinical evidence to guide their use for shoulder pathologies such as cuff tears and osteoarthritis.
Abstract, as published

The field of orthopedic surgery has seen a rapid increase in the use of various biologic agents for the treatment of common musculoskeletal injuries. Most biologic agents attempt to harness or mimic naturally occurring growth factors, cytokines, and anti-inflammatory mediators to improve tissue healing and recovery. The most commonly used biologic agents are platelet-rich plasma and cells derived from bone marrow aspirate and adipose tissue. These agents have become increasingly popular despite a relative dearth of clinical data to support their use. Much confusion exists among patients and physicians in determining the role of these agents in treating common shoulder pathologies, such as glenohumeral osteoarthritis, rotator cuff tears, and tendinopathy. This article reviews the basic science and clinical evidence for the most commonly used biologic agents in the management of common shoulder pathology.

Featured in the 2026-09-17 issue.

← Malunited Forearm Fractures in ChildrenEpidemiology of Acromioclavicular Sprains in the National Foo… →

The Reduction is a free email digest of newly published orthopaedic literature — a handful of new papers in the subspecialties you choose, each summarized like this one. Subscribe free or browse the archive.